Literature DB >> 11509617

CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism.

D H Canaday1, R J Wilkinson, Q Li, C V Harding, R F Silver, W H Boom.   

Abstract

Cytotoxic effector phenotype and function of MHC-restricted Mycobacterium tuberculosis (MTB)-reactive CD4(+) and CD8(+) T lymphocytes were analyzed from healthy tuberculin skin test-positive persons. After stimulation in vitro with MTB, both CD4(+) and CD8(+) T cells up-regulated mRNA expression for granzyme A and B, granulysin, perforin, and CD95L (Fas ligand). mRNA levels for these molecules were greater for resting CD8(+) than CD4(+) T cells. After MTB stimulation, mRNA levels were similar for both T cell subsets. Increased perforin and granulysin protein expression was confirmed in both in CD4(+) and CD8(+) T cells by flow cytometry. Both T cell subsets lysed MTB-infected monocytes. Biochemical inhibition of the granule exocytosis pathway in CD4(+) and CD8(+) T cells decreased cytolytic function by >90% in both T cell subsets. Ab blockade of the CD95-CD95L interaction decreased cytolytic function for both T cell populations by 25%. CD4(+) and CD8(+) T cells inhibited growth of intracellular MTB in autologous monocytes by 74% and 84%, respectively. However, inhibition of perforin activity, the CD95-CD95L interaction, or both CTL mechanisms did not affect CD4(+) and CD8(+) T cell mediated restriction of MTB growth. Thus, perforin and CD95-CD95L were not involved in CD4(+) and CD8(+) T cell mediated restriction of MTB growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509617     DOI: 10.4049/jimmunol.167.5.2734

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  69 in total

1.  ATP and control of intracellular growth of mycobacteria by T cells.

Authors:  David H Canaday; Reza Beigi; Richard F Silver; Clifford V Harding; W Henry Boom; George R Dubyak
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells.

Authors:  Gucheng Zeng; Crystal Y Chen; Dan Huang; Shuyu Yao; Richard C Wang; Zheng W Chen
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

Review 3.  Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy.

Authors:  Deborah M Brown
Journal:  Cell Immunol       Date:  2010-02-24       Impact factor: 4.868

4.  Human lung immunity against Mycobacterium tuberculosis: insights into pathogenesis and protection.

Authors:  Stephan Schwander; Keertan Dheda
Journal:  Am J Respir Crit Care Med       Date:  2010-11-12       Impact factor: 21.405

Review 5.  Striking the right immunological balance prevents progression of tuberculosis.

Authors:  Shachi Pranjal Vyas; Ritobrata Goswami
Journal:  Inflamm Res       Date:  2017-07-15       Impact factor: 4.575

6.  IL-9 promotes anti-Mycobacterium leprae cytotoxicity: involvement of IFNgamma.

Authors:  M R Finiasz; M C Franco; S de la Barrera; L Rutitzky; G Pizzariello; M del Carmen Sasiain; J-C Renauld; J Van Snick; S Fink
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

7.  HIV-1 and the immune response to TB.

Authors:  Naomi F Walker; Graeme Meintjes; Robert J Wilkinson
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

Review 8.  Evasion and subversion of antigen presentation by Mycobacterium tuberculosis.

Authors:  A Baena; S A Porcelli
Journal:  Tissue Antigens       Date:  2009-06-25

Review 9.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

10.  Immune biology of macaque lymphocyte populations during mycobacterial infection.

Authors:  X Lai; Y Shen; D Zhou; P Sehgal; L Shen; M Simon; L Qiu; N L Letvin; Z W Chen
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.